Sermorelin
A growth hormone-releasing hormone (GHRH) analog that prompts the pituitary to release your own growth hormone.
Learn about Sermorelin →Peptide therapy
Peptide therapy, limited to what can lawfully be prescribed
Medical review pending · Last updated
Interest in peptides has exploded, and so has the gray market. We only list peptides a licensed provider can prescribe in the U.S. today, with plain notes on regulatory status and evidence. Status last reviewed 2026-11-03.
Regulatory note: Rules changed several times in 2026. On October 28, 2026, HHS announced an interim policy (published in the Federal Register on October 30, 2026) allowing licensed pharmacies to compound six peptides under strict conditions while FDA rulemaking proceeds. Status can change; we will update this page. New here? Read what are peptides, are peptides legal in 2026?, or sermorelin vs. tesamorelin.
Peptides a licensed provider may prescribe
Tesamorelin
An FDA-approved GHRH analog for excess abdominal fat in adults with HIV-associated lipodystrophy.
Learn about Tesamorelin →Bremelanotide (PT-141)
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Learn about Bremelanotide (PT-141) →BPC-157
Compounded only under HHS's interim enforcement-discretion policy (announced Oct 28, 2026). Not FDA-approved.
Learn about BPC-157 →TB-500
Compounded only under HHS's interim enforcement-discretion policy (announced Oct 28, 2026). Not FDA-approved.
Learn about TB-500 →MOTS-c
Compounded only under HHS's interim enforcement-discretion policy (announced Oct 28, 2026). Not FDA-approved.
Learn about MOTS-c →KPV
Compounded only under HHS's interim enforcement-discretion policy (announced Oct 28, 2026). Not FDA-approved.
Learn about KPV →Epitalon
Compounded only under HHS's interim enforcement-discretion policy (announced Oct 28, 2026). Not FDA-approved.
Learn about Epitalon →Semax
Compounded only under HHS's interim enforcement-discretion policy (announced Oct 28, 2026). Not FDA-approved.
Learn about Semax →Peptides we do not offer, and why
| Peptide | Reason excluded (as of 2026-11-03) |
|---|---|
| CJC-1295 | Not on the 503A Bulks List; PCAC voted against inclusion (Dec 2024). No HHS interim policy coverage. |
| Ipamorelin | Not on the 503A Bulks List; PCAC voted against inclusion (Oct 2024). No HHS interim policy coverage. |
| Thymosin alpha-1 | Not on the 503A Bulks List; PCAC voted against inclusion (Dec 2024). No HHS interim policy coverage. |
| AOD-9604 | Nomination withdrawn (2024); not on the 503A Bulks List; not covered by the interim policy. |
| Selank | Nomination withdrawn (2024); not on the 503A Bulks List; not covered by the interim policy. |
| GHK-Cu (injectable) | Removed from FDA's 503A category lists in April 2026 after nomination withdrawal; PCAC review pending (before Feb 2027). |
| LL-37 (cathelicidin) | Removed from Category 2 in April 2026; PCAC review pending (before Feb 2027). |
| Melanotan II | Removed from Category 2 in April 2026; PCAC review pending (before Feb 2027). |
| Dihexa | Removed from Category 2 in April 2026; PCAC review pending (before Feb 2027). |
| PEG-MGF | Removed from Category 2 in April 2026; PCAC review pending (before Feb 2027). |
| DSIP (emideltide) | PCAC did not recommend inclusion (July 2026); excluded from the HHS interim policy. |
| MK-677 (ibutamoren) | Remains on FDA Category 2 (significant safety risks); also not a peptide. |
| Any multi-ingredient peptide "blend" | The HHS interim policy covers single-active-ingredient products only. |
We also never offer "research use only" products.
Frequently asked questions
What is peptide therapy?
Peptide therapy uses short chains of amino acids as medicines. Some are FDA-approved for specific conditions; others may be compounded by licensed pharmacies under federal rules.
Why don't you offer CJC-1295 or ipamorelin?
As of November 2026 they are not on FDA's 503A Bulk Drugs List, FDA advisers voted against adding them in 2024, and they are not covered by HHS's October 2026 interim policy. We only feature peptides that can be lawfully prescribed now.
Are compounded peptides FDA-approved?
No. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.
Sources
- Federal Register: HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, published Oct 30, 2026)
- HHS: Enforcement discretion policy text and Appendices A-B (PDF)
- FDA: Bulk drug substances nominated for use in compounding under section 503A (Categories 1-3, PDF)
- FDA: Bulk drug substances used in compounding (503A and 503B rules)
- Federal Register 2026-07361: PCAC notice of meeting on bulk drug substances nominated for the 503A list (Apr 16, 2026)
- FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026
- FDA: Compounding and the FDA, questions and answers
Sources are listed for reference and do not imply endorsement. Regulatory status can change; check the date above.
Peptide care is coming soon
Care through independent licensed clinicians, starting in select states.